What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one Read More
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer
By Ryan Scott June 1, 2024 Key Takeaways Patients Read More
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2–Risk, HR+/HER2– Early Breast Cancer
By Ryan Scott June 1, 2024 A lower risk of Read More
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer Read More
Genomic Testing Transforms Breast Cancer Care and Treatment Success
In an insightful interview with Dr. William Audeh, MD, Read More
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleDr. Nathalie Johnson Calls for Medical Community to Move to Action for Equality in Genomic Testing for Black Women
Dr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her opinion in STAT News article on why Black women with breast cancer experience higher death rates and how utilizing a more advanced genomic test can provide a more comprehensive understanding and accurate risk evaluation.
Read the Article
